Important advances for millions with sexual dysfunction.
Invicorp® is a highly safe and effective treatment for erectile dysfunction (ED), a condition that affects more than 100 million men worldwide. Invicorp®, a combination of vasoactive intestinal peptide (VIP) and phentolamine mesylate (PMS), has shown excellent results in a wide range of patients, many of whom have failed on other therapies for the treatment of ED. VIP is a 28-amino-acid peptide found naturally in the male and female urogenital tracts, as well as in the central and peripheral nervous systems. It causes erection by binding to smooth-muscle receptors in the corpus cavernosum, inducing smooth-muscle relaxation and increased blood flow. In completed Phase III clinical trials conducted in the United Kingdom, Denmark, Ireland and Australia, Invicorp® demonstrated outstanding efficacy and safety. The most frequently reported side effect was transient facial flushing, which typically subsided within minutes after use.
Unlike many other ED therapies, Invicorp® has no known contraindications. Other significant advantages include: rapid onset of erection after stimulation – typically within two-to-five minutes; the ability to induce an erection up to 2 ½ hours after administration with natural termination of an erection after ejaculation, as well as efficacy in the treatment of organic ED. Invicorp® is administered using a novel drug delivery system that renders the self-injection process uncomplicated and pain free.
A recent Decision Resources, Inc. study indicated the medical community’s enthusiasm in Invicorp®. Among the findings, the study showed that intracavernous injection therapies will continue to be the most effective second-line treatments for moderate-to-severe ED. Based on physician enthusiasm, Invicorp’s® high therapeutic index and advantages over current injection therapies, the study predicted that Invicorp® could become the injection therapy of choice.
(See Decision Resources Overview).
Invicorp® is expected to capture a significant share of the moderate-to-severe ED market and become the therapy of choice for second-line ED treatment (after oral therapies have been attempted). Invicorp® is also expected to become first-line treatment for those with diabetes, heart disease and severe organic ED.
Analysts predict the world wide ED market will generate about $3.8 billion by 2003. Senetek is well-positioned to compete in that market. To date, regulatory approval has been granted in Denmark, New Zealand and the United Kingdom. Senetek is currently seeking pan-European approval of Invicorp® under the Mutual Recognition Process.
Erectile Dysfunction video